NovoCure (NVCR) Share-based Compensation (2016 - 2026)
NovoCure's Share-based Compensation history spans 13 years, with the latest figure at $63.0 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 113.21% to $63.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $138.3 million, a 11.07% decrease, with the full-year FY2025 number at $104.8 million, down 34.49% from a year prior.
- Share-based Compensation hit $63.0 million in Q1 2026 for NovoCure, up from $19.8 million in the prior quarter.
- Over the last five years, Share-based Compensation for NVCR hit a ceiling of $63.0 million in Q1 2026 and a floor of $17.4 million in Q4 2023.
- Historically, Share-based Compensation has averaged $32.4 million across 5 years, with a median of $29.6 million in 2025.
- Biggest five-year swings in Share-based Compensation: surged 259.89% in 2024 and later plummeted 68.42% in 2025.
- Tracing NVCR's Share-based Compensation over 5 years: stood at $29.8 million in 2022, then tumbled by 41.45% to $17.4 million in 2023, then surged by 259.89% to $62.8 million in 2024, then plummeted by 68.42% to $19.8 million in 2025, then surged by 217.97% to $63.0 million in 2026.
- Business Quant data shows Share-based Compensation for NVCR at $63.0 million in Q1 2026, $19.8 million in Q4 2025, and $29.3 million in Q3 2025.